NIH R01s: No Longer the Best Science

By Les Costello NIH R01s: No Longer the Best Science Funding preferences penalize senior investigators, lower the quality of science. © DAN PAGE For 60 years, the US National Institutes of Health R01 research grant mechanism has aimed at funding the highest-quality science to address the important contemporary issues. That began to change in 2008, after NIH Director Elias Zerhouni issued the goal to “Fund the best science, by the best scienti

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

For 60 years, the US National Institutes of Health R01 research grant mechanism has aimed at funding the highest-quality science to address the important contemporary issues.

That began to change in 2008, after NIH Director Elias Zerhouni issued the goal to “Fund the best science, by the best scientists…” 1 As a result, new guidelines, requirements, and considerations have been introduced. Unfortunately, these changes are antithetical and counterproductive to achieving Dr. Zerhouni’s stated goal.

A New Paradigm for NIH Grants

Stimulus Application? Not Me

Losing your lab

The new process has transformed the R01 mechanism into a channel that provides funds for the training and development of new and early-stage investigators (ESIs).

New directives require that “NIH will support New Investigator R01 awards at success rates comparable to those for established investigators submitting new R01 applications.” 2 Even recipients of several already-existing NIH training and development grant programs qualify as ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Les Costello

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo